Website Notice Block

Washington, D.C.  20549
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of July 2022
Commission File Number: 001-36349
                  MediWound Ltd.                   
(Translation of registrant’s name into English)

42 Hayarkon Street
Yavne, 8122745 Israel
 (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒          Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   __

On July 12, 2022, MediWound Ltd. (the “Company”) presented certain market research during a KOL event and made available the presentation on its website. A copy of the presentation is attached hereto as Exhibit 99.1. The fact that the presentation is being made available and furnished herewith is not an admission as to the materiality of any information contained in the presentation. The information contained in the presentation is being provided as of July 12, 2022 and the Company does not undertake any obligation to update the presentation in the future or to update forward-looking statements to reflect subsequent actual results.



Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: July 12, 2022
/s/ Boaz Gur-Lavie  
    Name: Boaz Gur-Lavie  
    Title:   Chief Financial Officer  



The following exhibit is filed as part of this Form 6-K:




Exhibit 99.1

 Market Landscape Analysis & EscharEx Market PotentialKevin FengOliver Wyman 

 In-depth interviews (N=30) with KOLs, community practitioners, payers in US / EU  Current & future treatment dynamics  Feedback on EscharEx profile and positioning  Pharmacoeconomic considerations  Web survey (N=200) fielded to quantify the opportunity for modeling (e.g. eligibility rate, tx rate, shares, etc.)  In-depth interviews with VLU treaters (2020) across diverse specialties to reflect range of treaters that see VLU patients (N=10, 45 min each)  Interviewees represented diverse geographic mix across the US  Discussion focused on clinical and commercial topics of interests related to the evaluation of EscharEx potential  Performed market sizing analysis for VLUs and DFUs  Triangulated estimates across range of sources including literature, syndicated market research, and analyst reports  Performed analog research to identify benchmarks to guide time to peak adoption estimates  Created a 10-year forecast for EscharEx in VLUs and DFUs  EscharEx market share estimates were based on prior rounds of market research  Output included VLU and DFU revenue estimates building to total EscharEx market potential  In-depth interviews with VLU / DFU treaters (2022) across specialties, including both Study PIs & EscharEx-naïve treaters (N=12, 45 min each)  Discussion focused on evaluating potential for EscharEx based on latest Phase 2 results  Updated forecast for EscharEx, integrating new findings from MR with prior rounds of research  Market Research Has Been Comprehensive  2015  2020  2020  2022  2020  Comprehensive and step-wise evaluation of EscharEx Potential based on latest clinical development plan & data 

 Chronic Wound Patient Journey: Key Sites of Care  Community patients may see home care nurse before wound is severe enough to be referred to clinic  Outpatient Clinic  Follow Up: Avg. 1-3X per week; majority receive home care follow up  Hospital Inpatient (<15%*)  Length of Stay: Avg. 1-2 weeks   Treaters: Variable; more access to surgical specialists  Home Care,  Nursing Homes, & Long Term Care  Majority of chronic wound patients require long-term follow-up care at home / nursing facility  Initial Follow Up: Avg. once every 2-3 days  Treaters: Community / home care nurses  Majority of chronic wounds present outpatient  GP / PCP  Hospital Units  Chronic Wound Patient  Also: general podiatry, diabetology, dermatology, vascular surgery  Wound Care Clinic  Treaters: Rotating panel of ~4-5 specialties or one specialized physician  Most wound care in US; etiology-specific clinics also exist  Home Care Nurse  DFU or Leg Ulcer Clinic  Treaters: ~2-4 diabetologists / podiatrists (DFUs) OR dermatologists / surgeons (VLUs); several nurses  A subset are triaged inpatient due to severity (need for surgical intervention), infection  Majority   Minority  Most chronic wounds in the U.S. are treated outpatient with follow-up visits 1-3x per week  *15% present in academic setting w/ more complex wounds; overall % inpatient likely lower 

 Debridement is SOC, But Method Is Not Standardized  Thorough Patient History  Rule out infection, x-ray or culture if needed  Assess perfusion / blood flow  Assess need for debridement  Basic Wound Work-Up  Advanced Wound Care  Debridement needed (~70% DFUs, ~55% VLUs)  Debridement not needed (~30% DFUs, ~45% VLUs)  Autolytic (± Sharp)  Enzymatic (± Sharp)   Mechanical  Surgical  Other (Ultrasound, Larvae)  Jet Lavage / Hydrosurgery  Continue TIME Framework  MajorityMinority  < 50% healing after 4 wks  Debridement Selection Process  ** Specialized centers only  Wound characteristics (e.g. complications)  Efficacy / outcomes  Patient considerations (e.g. tolerability)  Site of care  Skill of practitioner required (i.e. training)  Time and/or frequency of debridement  Cost & reimbursement  Input of other HCPs involved in patient care  Factors Determining Choice of Debridement Method  Decreasing Frequency of Use  START  Sharp (Bedside), Alone  Debridement Method Selection  Decreasing Importance  Wound characteristics, efficacy, and patient considerations are top influencers of choice 

 2022 US DFU Epidemiology Estimate  2022 US VLU Epidemiology Estimate  Triangulation Indicates 1M VLUs and 1.1M DFUs Annually Eligible for Debridement  1.1M active DFUs in a given year  70% of DFUs undergo debridement  770K DFUs undergoing debridement in a given year   Millions of Patients  1.0M incident patients with an active VLU, eligible for tx  55% of DFUs undergo debridement  560K VLUs undergoing debridement in a given year  

 *Estimates are based on small study (N=12)  VLU Debridement Approach Driven By Site Of Care; Sharp Remains SoC Across Wound Care Clinics  Current Debridement Practices*  Commentary  “All DFU / VLU patients get sharp debridement. If they are able to tolerate it, it is probably the most effective debridement method of removing nonviable tissue, as well as bioburden in the wound. ”  – Podiatrist #5 (Non-PI)  29%  29%  Legend  “Some of the wounds are more superficial, sometimes the topical agent alone is enough...if they are not responding, yeah, then we would have to step it up and go to a different method, probably add sharp debridement in ”  – Dermatologist #2 (Non-PI)  Source: OW Primary Research (6/2022)  All VLU patients seen at WC clinics will undergo debridement  In contrast, in home health setting only 1/3 VLUs are debrided; other 2/3 of patients have wounds that are caught and managed early by nurses, and thus can heal without needing debridement  Choice of debridement technique is highly dependent on site of care   Surgeons and clinicians at wound care clinics, regardless of medical specialty, perform sharp debridement as SOC for all patients   In other specialty practices, such as dermatology, clinicians much more split between sharp vs. non-sharp   Nursing home / home health settings depend enzymatic or autolytic  While sharp is SoC at WC clinics, pain can be a barrier to use (particularly in VLUs), leading HCPs to defer to a topical instead  Sharp + enzymatic / autolytic combinations are also commonly used, with sharp used as primary method (e.g. 1-2x per week) and topical as maintenance (applied in between sharp visits) 

 Current Enzymatic Use is Limited, Due to Perception of Low Efficacy and High Cost  Current Enzymatic SOC Perception  Commentary  Efficacy  Less Favorable  More Favorable  Safety  Less Favorable  More Favorable  Dosing & Administration  Less Favorable  More Favorable  Cost  Less Favorable  More Favorable  Efficacy: HCP opinion of enzymatic efficacy generally ranges from very low to moderate; most still utilize to some degree but note limited efficacy due to slow speed of debridement  Efficacy may be further reduced if unable to comply with recommended 1x daily regimen  A few HCPs cited Panafil as a much faster enzymatic debrider, prior to recall  Safety: Considered very safe, with minimal AEs / pain  Dosing & Administration: Generally considered easy to use / apply, given potential for self or care-giver application; recommended regimen is typically 1x / day  Slow speed of debridement leads to extended use (average of 6-8 weeks), which can also influence patient compliance with daily regimen  Cost: High cost often cited as major disadvantage relative to efficacy,   Average cost of ~$298 / 30g tube, reimbursed under pharmacy benefit; prior research showed patients use ~6-8 tubes on average (total cost of treatment ~$2000)  “Enzymatic use is a little bit of an expense thing. It is a little bit of an availability thing that sometimes it is just harder to get, so that I use them less partly for that reason. I do think they probably work a little bit better than autolytic, but I am not honestly even sure of that.”  – Dermatologist #2 (Non-PI)  “It is efficacious compared to Vaseline... But is it tremendously efficacious? Tremendously helpful? I question that notion… Oftentimes, my patients cannot afford it, or the patient has to pay most of it because their prescription plan may or may not cover it.”  – Podiatrist #2 (Non-PI)  Source: OW Primary Research (6/2022) 

 Physicians note that while sharp is efficacious and affordable, there remain situations where sharp cannot be utilized, driving unmet need for efficacious and affordable non-sharp alternatives:  Speed: Ideal product should work faster than current topical modalities, as speed of debridement cited by most HCPs as greatest unmet need  Affordability: Novel agent should be affordable and similar to current alternatives; experts note higher cost or lack of coverage by insurance as deterrents to using current modalities  Application frequency / duration: Daily application over long periods of time required by current enzymatic treatment; alternative ideally requires fewer applications  Gap in market remains after recall of papain products (seen as much more effective than current enzymatic SoC), which were used commonly when sharp was not suitable  A few physicians have noted interest in few products in the pipeline (e.g. hydro-debriders, topical stem cell agents); however, most HCPs have limited optimism or knowledge of therapeutic agents in the pipeline  HCPs Report Significant Need For Faster, More Efficacious Topical Debridement Agent  “I would like to see a product that actually works within a reasonable period of time. Not eight weeks but maybe something within four weeks. Even with compliant patients with a wound that’s a couple centimeters in diameter, it’s going to take eight weeks. It shouldn’t take that long.   –Podiatrist #1 (Non-PI)  “Enzymatic is not great at debriding everything and it takes a long time …something that will debride faster is what we are looking for. Sharp is really the only fast debridement modality, but it is not always applicable. If we had something that was able to debride the wound faster without causing pain, that would be ideal.”  –Podiatrist #4 (PI)  Source: OW Primary Research (6/2022)  Unmet Need  Pipeline 

 EscharEx Perceived As Highly Efficacious, Demonstrating Clear Benefit Over Current Options  EscharEx Perception by Attribute  Perception of efficacy is extremely favorable, with HCPs immediately noting EscharEx’s faster speed of debridement vs. current agents  Primary and secondary clinical endpoints believed to be most important, with clearest benefit demonstrated by incidence of and time needed to achieve complete debridement  Pharmacology data seen as helpful in supporting clinical endpoints, though less important than primary / secondary  HCPs often expect lower biofilm / bacterial load as natural consequence of better debridement (and thus may not emphasize importance of seeing pharmacology data)  However, a few physicians noted biofilm score / bacterial load has been emerging with increasing level of importance in wound healing field  Few HCPs want to see superior efficacy in wound closure, given faster debridement should translate to faster wound closure; however, most believe that a superiority endpoint is not essential for a debridement agent, and comparable incidence / time data is sufficient  If superior efficacy for wound closure was shown, HCPs believe this may support even further adoption of Product X and justify higher costs  “The product looks like it works very well. They are basically saying you only need five applications of this product to get the wound to a granular bed, which is great because you do not usually see that.”  –Podiatrist #5 (PI)  “I think biofilm is increasingly important because of literature supporting better ways of trying to break bioburden down. It is more on my radar today than it was 10 years ago or even two years ago. It’s innovative in a way to keep that as one of your endpoints. ”    –Podiatrist #6 (PI)  Primary Endpoint  Incidence to complete debridement  Secondary Endpoint  Time to achieve complete debridement  # applications needed for debridement  >75% Granulation tissue incidence   Pharmacology  Biofilm Score  Bacterial load via fluorescence  Wound Closure  Incidence of wound closure  Time to wound closure  Source: OW Primary Research (6/2022)  Commentary  Efficacy  Less Favorable  More Favorable  Less Important More Important   Relative Importance to Profile 

 Minimal Issues with EscharEx Safety Or Dosing & Administration  “My perception wouldn’t change from 5 to 8 applications. I mean current enzymatic treatment, it’s 100 applications, you know. So, they could go to 20 applications, and it still wouldn’t make any difference to me.”  –Dermatologist #2 (Non-PI)  “There were no adverse events. There were no allergic reactions to the product. It seems like it is a safe product to use. 120 patients to evaluate the tolerability and safety of the product, it is a good study. ”  –Podiatrist #5 (PI)  Source: OW Primary Research (6/2022)  EscharEx Perception by Attribute  Commentary  Safety  Less Favorable  More Favorable  Dosing & Administration  Less Favorable  More Favorable  Safety: Most HCPs raised minimal issues with safety profile (perceiving as safe), with several noting how crucial safety is when considering high opinion of enzymatic agent’s safety today  A few HCPs requested additional data surrounding pain (or absence of pain) upon application, highlighting importance of patient comfort  Dosing & Administration: Perceived as favorable, particularly given short regimen (daily applications for 5 days) compared to current enzymatic agent and potential for home-application  Potential for range of 5-8 applications did not raise any concerns, as even 8 days is significantly faster than current enzymatic agent; few HCPs noted minor benefit with 7 or fewer days, to fit logistically into weekly clinical visits  HCPs also amenable to first application in clinic, followed by subsequent home applications 

 Given Strong Profile of EscharEx, HCPs Reported Expansion of Enzymatic Use Drawing From Other Classes  Future Debridement Practices  HCPs expect aggressive expansion of enzymatic segment across VLUs & DFUs, with slightly higher use in VLUs given additional barrier that pain poses to sharp use; similarly, HCPs expect greater use of enzymatic only in VLUs (vs. DFUs), but greater use of sharp + enzymatic in DFUs (vs. VLUs)  VLU  DFU  Legend  29%  55%  29%  52%  Source: OW Primary Research (6/2022)  EscharEx is anticipated to draw share from all other debridement modalities   (including sharp only, autolytic only, and sharp + autolytic) 

 ~2.1M  VLU and DFU patients eligible for debridement in a given year  55% - 70%  Percentage of wounds debrided  43%  Percentage debrided by enzymatic methods  (Research indicates that EscharEx can expand enzymatic market (~20% debrided by enzymatic methods today) if superior to current enzymatic agent and more cost effective)  70%  Anticipated EscharEx market share based on superiority  5 Years-to-Peak Share   CoT: $1,500 (base) / $1,800 (upside) / $1,200 (downside)  CoT: based on 5 applications on average @ $300 per application  U.S. Market Opportunity  EscharEx TAM for VLUs and DFUs is estimated at ~$2B in the U.S.  Market research and physician feedback suggest that EscharEx potential market share at ~30%  Market potential estimates based on above assumptions, and does not account for market access and other considerations that may impact actual figures and are subject to EscharEx approval b FDA. EscharEx is an investigational drug under development, not approved in any jurisdiction